TY - JOUR
T1 - Treatment of Acute Myelogenous Leukemia
AU - Morley, Alexander A.
AU - Ghaddar, Habib
AU - Anderlini, Paolo
AU - Estey, Elihu
AU - Meisenberg, Barry
AU - Zittoun, Robert
AU - Mandelli, Franco
AU - Suciu, Stefan
PY - 1995/6/22
Y1 - 1995/6/22
N2 - To the Editor: The report by Zittoun et al. (Jan. 26 issue)1 on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.
AB - To the Editor: The report by Zittoun et al. (Jan. 26 issue)1 on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.
UR - http://www.scopus.com/inward/record.url?scp=0029026806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029026806&partnerID=8YFLogxK
U2 - 10.1056/NEJM199506223322515
DO - 10.1056/NEJM199506223322515
M3 - Letter
C2 - 7760879
AN - SCOPUS:0029026806
SN - 0028-4793
VL - 332
SP - 1717
EP - 1719
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 25
ER -